RSPHvsXLVIETF Comparison
VS
ETF 2
XLVI
State Street Health Care Select Sector SPDR Premium Income Fund
This fund is part of
Options Strategies
-0.19%
Invesco S&P 500® Equal Weight Health Care ETF (RSPH) belongs to the US Health Care segment. State Street Health Care Select Sector SPDR Premium Income Fund (XLVI) is part of the Options Strategies segment. Both ETFs have the same top 2 sector exposures: Healthcare and Consumer Non-Cyclicals. RSPH is more expensive with a Total Expense Ratio (TER) of 0.4%, versus 0.35% for XLVI. RSPH is up 15.91% year-to-date (YTD) with +$51M in YTD flows. XLVI performs worse with 7.03% YTD performance, and +$15M in YTD flows. Run a side-by-side ETF comparison of RSPH and XLVI below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
RSPH vs XLVI performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/16/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | RSPH XLVI | +2.74%-2.58% | +14.94%+4.46% | +15.91%+7.03% | +28.02%+17.87% | +33.49%n/a | +21.49%n/a |
| Flows | RSPH XLVI | +$98M+$5M | +$142M+$11M | +$51M+$15M | +$32M+$25M | -$263M- | -$272M- |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | RSPH XLVI | +20.92%+12.16% | +16.74%+11.15% | +15.90%n/a | +16.80%n/a |
| Max drawdown | RSPH XLVI | -5.57%-4.94% | -10.87%-8.21% | -16.96%n/a | -21.91%n/a |
| Max drawdown duration | RSPH XLVI | 28d22d | 116d115d | 434dn/a | 817dn/a |
Trading data
RSPH | XLVI | |
Last sale 9/17/2026 at 1:30 PM | $36.97 | $26.18 |
| Previous close 09/16/2026 | $36.78 | $26.00 |
| Consolidated volume 09/16/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
XLVI
is actively managed and doesn’t replicate an indexRSPH | XLVI | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/17/2026 at 1:30 PM
Live
Closed
RSPH | XLVI | |
|---|---|---|
| Last price | $36.97 | $26.18 |
| 1D performance | +0.52% | +0.67% |
| AuM | $903.50 M | $26.57 M |
| E/R | 0.4% | 0.35% |
Characteristics
RSPH | XLVI | |
|---|---|---|
| Management strategy | Passive | Active |
| Provider | Invesco | State Street Investment Management |
| Benchmark | S&P 500 Equal Weight Health Care Index | - |
| N° of holdings | 59 | 59 |
| Asset class | Equities | - |
| Trailing 12m distribution yield | Join | Join |
| Inception date | November 1, 2006 | July 30, 2025 |
| ESG | No | No |
Advertisement
Exposure
Countries
RSPH
USA
96.6%
Other
3.4%
XLVI
USA
97.34%
Other
2.66%
Sectors
RSPH
Healthcare
98.34%
Other
1.66%
XLVI
Healthcare
97.32%
Other
2.68%
Diversification
RSPH
Total weight of top 15 holdings out of 15
28.14%
XLVI
Total weight of top 15 holdings out of 15
71.63%
Top 15 holdings
Data as of July 31, 2026
RSPH
Bio-Techne Corp.
2.10%
IQVIA Holdings, Inc.
2.08%
Veeva Systems, Inc.
1.95%
Charles River Laboratories International, Inc.
1.93%
Mettler-Toledo International, Inc.
1.89%
Baxter International, Inc.
1.87%
DaVita, Inc.
1.86%
Abbott Laboratories
1.86%
Incyte Corp.
1.85%
Thermo Fisher Scientific, Inc.
1.83%
Moderna, Inc.
1.82%
AbbVie, Inc.
1.79%
Universal Health Services, Inc.
1.78%
Regeneron Pharmaceuticals, Inc.
1.77%
Quest Diagnostics, Inc.
1.77%
XLVI
Eli Lilly & Co.
15.45%
Johnson & Johnson
10.49%
AbbVie, Inc.
7.54%
UnitedHealth Group, Inc.
6.40%
Merck & Co., Inc.
5.47%
Thermo Fisher Scientific, Inc.
3.63%
Amgen, Inc.
3.53%
Abbott Laboratories
3.13%
Gilead Sciences, Inc.
2.75%
Pfizer Inc.
2.42%
Bristol Myers Squibb Co.
2.27%
CVS Health Corp.
2.27%
Intuitive Surgical, Inc.
2.13%
Danaher Corp.
2.09%
Vertex Pharmaceuticals, Inc.
2.06%
Frequently asked questions about RSPH and XLVI
How have the RSPH and XLVI ETFs performed in 2026?
As of September 16, 2026, RSPH is up 15.91% year-to-date (YTD), while XLVI has returned 7.03%. That puts RSPH better performer ahead so far this year.
Which ETF is attracting more investor money: RSPH or XLVI?
Year-to-date, the RSPH ETF saw +$51M in flows, compared to +$15M for XLVI.
Which ETF is more volatile: RSPH or XLVI?
Over the past year, RSPH had a volatility of 16.74%, while XLVI experienced 11.15%.
Which ETF is bigger: RSPH or XLVI?
As of September 16, 2026, RSPH holds $903.50 M in assets under management (AUM), while XLVI manages $26.57 M.
What sectors do the RSPH and XLVI ETFs invest in?
RSPH leans toward sectors like Healthcare. Meanwhile, XLVI focuses on Healthcare.
What are the top holdings of the RSPH ETF and XLVI ETF?
RSPH top holdings include Bio-Techne Corp., IQVIA Holdings, Inc. and Veeva Systems, Inc.. XLVI holds in its top three: Eli Lilly & Co., Johnson & Johnson and AbbVie, Inc..
Which ETF is more diversified: RSPH or XLVI?
RSPH holds 59 securities with 28.14% of its assets in the top 15. XLVI has 59 securities and a top 15 weight of 71.63%.
Advertisement
Latest news about RSPH & XLVI
Advertisement
